Metagenomi Therapeutics, Inc.
MGXNasdaqCIK 1785279HealthcareFiscal year ends Dec 31
Reports and events: 40 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2220:49 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-397037 |
| 2026-08-1016:12 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-342400 |
| 2026-08-1016:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342388 |
| 2026-06-1018:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-264392 |
| 2026-05-1116:10 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-216774 |
| 2026-05-1116:09 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-216763 |
| 2026-04-2716:55 ET | DEF 14A | Proxy statementPeriod 2026-04-21 | 0001193125-26-182325 |
| 2026-03-0516:14 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-093976 |
| 2026-03-0516:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093943 |
| 2026-01-1209:27 ET | 8-K | 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-009928 |
| 2025-11-1208:42 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-276150 |
| 2025-11-1208:39 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-276135 |
| 2025-10-0116:47 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001193125-25-226878 |
| 2025-08-1216:09 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-107308 |
| 2025-08-1216:07 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-107304 |
| 2025-06-1118:20 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-084529 |
| 2025-05-1407:15 ET | 8-K | 8.01 Other events | 0000950170-25-070906 |
| 2025-05-1316:40 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-070463 |
| 2025-05-1316:35 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-070448 |
| 2025-04-2816:01 ET | DEF 14A | Proxy statementPeriod 2025-04-25 | 0000950170-25-059276 |
| 2025-03-1717:01 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-25-040453 |
| 2025-03-1716:06 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-040238 |
| 2025-03-1716:01 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-040217 |
| 2025-01-1608:59 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-006028 |
| 2024-12-1021:22 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-134733 |
| 2024-11-1316:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126317 |
| 2024-11-1316:01 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-126273 |
| 2024-09-0316:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-102805 |
| 2024-08-1408:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096673 |
| 2024-08-1408:00 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-096665 |
| 2024-05-1416:08 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-059532 |
| 2024-05-1416:04 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-059504 |
| 2024-05-0116:01 ET | 8-K | 1.02 Termination of a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-051238 |
| 2024-03-2709:23 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-036847 |
| 2024-03-2708:44 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-036838 |
| 2024-02-1316:06 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-033697 |
| 2024-02-0716:07 ET | S-1/A | Registration statement, amended | 0001193125-24-026662 |
| 2024-02-0506:11 ET | S-1/A | Registration statement, amended | 0001193125-24-023377 |
| 2024-01-0806:08 ET | S-1/A | Registration statement, amended | 0001193125-24-003810 |
| 2024-01-0517:16 ET | S-1 | Registration statement | 0001193125-24-003477 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.